**Author details**

Mounia Bendari1 \*, Sofia Sraidi2 and Nisrine Khoubila<sup>2</sup>

1 Mohammed VI University of Health Sciences (UM6SS), Casablanca, Morocco

2 Faculty of Medicine and Pharmacy of Casablanca, Hassan II University, Casablanca, Morocco

\*Address all correspondence to: bendarimounia@gmail.com

© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/ by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**99**

*Haematological Malignancies: Overview of the Recent Progresses in Genetics*

Council adult and children's leukaemia working parties. The importance of diagnostic Cytogenetics on outcome in AML: Analysis of 1612 patients entered into the MRC AML10 trial. Blood.1998;92(7):2322-2333

[10] Döhner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Büchner T, et al. Diagnosis and management of

recommendations from an international

[11] Cortes JE, Kantarjian H, Foran JM, et al. Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status. Journal of Clinical

AML in adults: 2017 ELN

expert panel. Blood. 2017;129(4)

Oncology. 2013;31: 3681-3687

of FLT3 with activity against resistanceconferring point mutants.

Blood. 2014;123:94-100

2012;26:2353-2359

12; 117(19): 5019-5032.

2007:412-417.

predisposition.

[12] Galanis A, Ma H, Rajkhowa T, et al. Crenolanib is a potent inhibitor

[13] Metzelder SK, Schroeder T, Finck A, et al. High activity of Sorafenib in FLT3- ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses. Leukemia.

[14] Campo E, and al, The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications Blood. 2011 May

[15] Dohner H. Implications of the molecular characterization of acute myeloid leukemia. Hematology

[16] Peterson L, Bloomfield CD, Döhner H, Niemeyer C, Godley L. Myeloid neoplasms with germline

*DOI: http://dx.doi.org/10.5772/intechopen.96913*

[2] Alessandro Gozzetti, michelle M le beau. Fluorescence in situ hybridization: Uses and limitations November 2000 Seminars in Hematology 37(4):320-333

[3] Esteban braggio Lessons from next-generation sequencing analysis in hematological malignancies Blood

Cancer Journal 3(7):e127

155:27-38

2(6):e558. D

Cytogenet 7(1):20.

[4] Kobold DC, Steinberg KM,

Larson DE, Wilson RK, Mardis ER. The next generation sequencing revolution and its impact on genomics. Cell 2013;

[5] Yurov YB, Iourov IY, Vorsanova SG, et al (2007) Aneuploidy and confi ned chromosomal mosaicism in the developing human brain. PLoS One

[6] Yurov YB, Vorsanova SG, Liehr T, et al (2014) X chromosome aneuploidy in the Alzheimer's disease brain. Mol

[7] M. Bendari and al, Current Cytogenetic Abnormalities in Acute Myeloid Leukemia. DOI: http://dx.doi.

org/10.5772/intechopen.91425

Moorman AV, Walker H, Chatters S, Goldstone AH, et al. Refinement of cytogenetic classification in acute myeloid leukemia: Determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated In the United Kingdom

Medical Research Council trials. Blood.

[9] Grimwade D, Walker H, Oliver F, et al. On behalf of the Medical Research

[8] Grimwade D, Hills RK,

2010;116(3):354-365

**References**

and Applications

[1] E. Mały. Cytogenetics in Hematooncology Recent Trends in Cytogenetic Studies–Methodologies 58 *Haematological Malignancies: Overview of the Recent Progresses in Genetics DOI: http://dx.doi.org/10.5772/intechopen.96913*
